Drug discovery targeting PAD enzymes to reduce NETosis, targeting pathogens, such as EBV, targeting other enzymes involved in epigenetic control and targeting polyamine synthesis and recycling enzymes should prove of greater value for eventual clinical use for prevention and control of autoimmune disorders. The gene discussed is PADI4; the disease is autoimmune disease.